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Background: The efficacy of deep brain stimulation (DBS) in Parkinson’s disease has 
been convincingly demonstrated in studies comparing motor performance with and with-
out stimulation, but characterization of the stimulation dose-response curves has been 
limited.
Methods: In a series of case studies, eight subjects with Parkinson’s disease and bilat-
eral DBS systems were evaluated at their clinically determined stimulation (CDS) and at 
three reduced amplitudes, ie, approximately 70%, 30%, and 0% of the CDS (MOD, LOW, 
and OFF, respectively). Performance was assessed using the motor section of the Unified 
 Parkinson’s Disease Rating Scale (UPDRS-III), which includes subscores for tremor, 
bradykinesia, gait, posture, and tapping. Data at the reduced settings were analyzed to 
determine if individual subjects demonstrated a threshold-like response, which was defined 
as a dose-response curve in which one decrement in stimulation accounted for $70% of 
the maximum change observed. Day-to-day variability was assessed using the CDS data 
from the three different days.
Results: In the dose-response curves, two subjects exhibited a threshold-like response, four 
exhibited a graded change, and two did not exhibit substantial changes. For some subjects, 
variability in CDS performance across the three days exceeded the change observed when 
reducing amplitude to the MOD setting. Comparisons across this set of eight subjects 
demonstrated that the mean UPDRS-III and all but one subscore significantly increased 
(performance degraded) when amplitude was reduced from CDS to the LOW and OFF 
conditions, but there were no significant changes when amplitude was reduced from CDS 
to the MOD condition.
Conclusion: Individual differences in the DBS dose-response curves may provide oppor-
tunities to optimize clinical performance. Day-to-day variability in motor performance 
cautions against the use of a single UPDRS measurement in clinical selection of DBS 
settings.
Keywords: deep brain stimulation, Parkinson’s disease, Unified Parkinson’s disease rating 
scale, motor performance
Introduction
For many people with Parkinson’s disease, deep brain stimulation (DBS) of the 
subthalamic nucleus can alleviate many symptoms of the disease, reduce levels of 
prescribed medication, and reduce medication-related side effects.1–4 Several stud-
ies have compared motor performance at patients’ clinically determined stimulation 
(CDS) settings, ie, the settings currently considered by the patient’s clinician to be 
optimal for the patient, with performance while the DBS system is turned off com-
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pletely.5–9 Although such studies demonstrate the benefits 
of using DBS, they do not provide much guidance to the 
clinician trying to select stimulation parameters that bal-
ance the tradeoffs between clinical effects and battery life. 
A more detailed understanding might help clinicians select 
more suitable stimulation parameters, but only a few studies 
have begun to investigate motor performance at intermediate 
stimulation settings. For example, one study investigated the 
effects of different combinations of contact location (rela-
tive to the subthalamic nucleus) and amplitude in patients 
with Parkinson’s disease. Given that the main focus was 
speech intelligibility, movement was only examined as a 
composite outcome.10 Another demonstrated that frequency 
and stimulation amplitude were the most important factors 
in alleviating tremor amplitude in patients with essential 
tremor, while varying pulse width had little effect.11 In both 
studies, patients were evaluated at the same amplitude values 
regardless of the settings that had been prescribed specifically 
for each patient.
The effects of varying pulse width, frequency, and 
stimulation amplitude on tremor, rigidity, and bradykinesia 
have been investigated in one study,12 but it did not evaluate 
effects on posture or gait. This report also concluded that 
varying pulse width did not have a clear effect on symptoms 
of  Parkinson’s disease, while stimulation amplitude was 
the most important factor in alleviating the parkinsonian 
triad.
In the series of case studies reported here, we evaluated 
five components of motor performance, ie, tremor, bradyki-
nesia, gait, posture, and tapping, in a population with Par-
kinson’s disease. Based upon the reports cited above,11,12 we 
focused our assessment on the effect of changing stimulation 
amplitude only. Motor performance was assessed using the 
motor section of the Unified Parkinson’s Disease Rating Scale 
(UPDRS-III). A UPDRS subscore was defined and assessed 
for each component. Given that the CDS amplitude setting 
can vary widely across individuals, we varied amplitude as a 
percentage of the CDS value to facilitate comparison across 
subjects. The CDS amplitude was defined as the ceiling, 
because stimulation amplitude is often set just below the 
threshold for adverse effects.12
Symptoms are known to vary daily in people with 
 Parkinson’s disease, with studies indicating that consecutive 
UPDRS measurements may vary by as much as 15%, yet 
many DBS studies have compared capabilities as assessed 
on different days.7,13 Therefore, we also examined motor per-
formance at the same stimulation condition over 3 different 
days to provide a daily baseline measurement.
Materials and methods
Subjects
Subjects who met the following criteria were recruited from 
the Movement Disorders Clinic at Banner Good  Samaritan 
Medical Center and Movement Disorder Specialists 
(Phoenix, AZ): age 18–80 years; diagnosis of idiopathic 
Parkinson’s disease with bilateral symptoms; a Hoehn and 
Yahr stage # 4 during the “medication-on/stimulation-on” 
condition; bilateral DBS system implanted in the subtha-
lamic nucleus for more than 3 months; willingness to sign 
the informed consent document; and ability to understand 
and follow directions.
Subjects were excluded if they presented with any of the 
following: significant hepatic, renal, cardiovascular, endo-
crine, respiratory, or unstable neurological disease aside from 
Parkinson’s disease; psychotic illness or chronic psychiatric 
disorder; history of drug dependence or intellectual impair-
ment; history of cerebral insult (causing delayed secondary 
Parkinson’s disease); a Hoehn and Yahr stage of 5 during the 
“medication-on/stimulation-on” condition; Parkinson’s plus 
syndrome; score $ 3 for UPDRS-II items 13–15 (falling 
unrelated to freezing, freezing when walking, and walking) 
during the “medication-on/stimulation-on”condition; or score 
$ 4 during the “medication-on/stimulation-on” condition for 
UPDRS III items.
Eight subjects (six males, two females) met the criteria and 
were enrolled in the study. The mean age at enrollment was 
59.5 ± 8.9 years. Mean time since diagnosis of Parkinson’s 
disease was 12.6 ± 4.0 years, and mean time since the first 
DBS surgery was 46.8 ± 23.7 months. The median Hoehn 
and Yahr stage at enrollment was 2.0, with a range of 2.0–3.0 
(Table 1). Seven of the subjects had previously been implanted 
with two Soletra® model 7426 neurostimulators (Medtronic 
Inc, Minneapolis, MN), while one subject (subject 2) had 
previously been implanted with one dual-program Kinetra® 
model 7428 neurostimulator (Medtronic Inc). The surgical 
placement technique used for all subjects included the use of 
microelectrode recordings. All subjects had been implanted 
with model 3387 macroelectrodes (Medtronic Inc) except 
subjects 4 and 8, who had been implanted with model 
3389 macroelectrodes (Medtronic Inc).
Experimental protocol
For each subject, data were collected during three sepa-
rate sessions, with a 1–4-week period between sessions 
(actual mean time between sessions 16.6 ± 5.0 days). All 
sessions were conducted at the Clinical Neurobiology 
and Bioengineering Research Laboratory at Banner Good 
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Samaritan Medical Center in Phoenix, AZ. All experimen-
tal procedures were approved by the center’s institutional 
review board and conducted in accordance with the cen-
ter’s guidelines and the Declaration of Helsinki. Informed 
consent was obtained from all subjects before participating 
in this research.
The experimental sessions were conducted during sub-
jects’ “medication-on” state in order to provide information 
about the dose-response characteristics of DBS as a supple-
ment to prescribed medication. Although several studies have 
defined the “medication-on” state as a suprathreshold dosage 
of levodopa, here the “medication-on” state represented 
the subjects’ daily living conditions to simulate a clinically 
relevant situation and allow the results to be readily trans-
ferred to the clinic.14 To ensure subjects were at the same 
point in their medication cycle, all three sessions occurred 
at the same time of day for each subject. The dosage of 
medication is reported as the levodopa equivalent daily dose 
in Table 1.15 Of note, one subject (subject 4) was not taking 
any antiparkinsonian medications throughout the course of 
the test sessions.
At each session, subjects were first evaluated at their 
currently programmed CDS settings and next with reduced 
amplitude stimulation  settings. This provided a consistent 
assessment of change in the same direction (ie, always 
from CDS to the altered condition) and a consistent 
assessment of the CDS settings (ie, it was always assessed 
before any changes to stimulation occurred). Reduced 
settings were always chosen relative to each subject’s CDS 
amplitude on that day, therefore allowing performance 
at reduced settings to be compared with performance at 
the settings currently determined to be optimal by the 
patient’s clinician. Subjects were given a 20-minute rest 
period after their DBS settings were reduced to allow any 
changes induced by the reduction to take full effect, which 
is equivalent to or longer than the calibration time in other 
studies that have evaluated motor performance at multiple 
stimulation settings.10–12,16 This rest period also limited the 
effects of subject fatigue and/or changes in drug efficacy 
that might have occurred with longer rest periods. The 
reduced amplitude setting on a given day was one of three 
conditions: MOD (approximately 70% of CDS), LOW 
(approximately 30% of CDS), and OFF (DBS stimulation 
completely switched off). Given the limited resolution on 
the implanted pulse generator, stimulation conditions were 
selected to be as close as possible to the target percent 
condition. Across subjects, the order in which the reduced 
amplitude settings were tested was randomized.
The CDS and reduced amplitude values, rate, pulse 
width, and active contacts used for each subject during each 
test session are given in Table 1. The mean CDS, MOD, and 
LOW amplitudes were 3.4 ± 0.8 V, 2.4 ± 0.6 V, and 1.0 ± 0.3 
V, respectively. The mean rate was 177 ± 17 Hz. The mean 
pulse width was 74 ± 16 µsec. Note that the study did not 
place any restrictions on changes in clinical prescription 
of medication or stimulation settings; those changes are 
noted in Table 1 and in the following sections of the text. 
In order to limit the effect of such intersession changes, the 
study primarily uses intrasession differences (between CDS 
and the altered condition) to characterize the response to 
changes in stimulation amplitude.
A trained DBS system operator queried the implanted 
pulse generator using a Model 8840 N’VisionTM clinician pro-
grammer (Medtronic Inc), recorded the current stimulation 
settings, and changed the stimulation settings. A researcher 
trained to administer the UPDRS evaluated items 18–31 
(the motor examination section) during all experimental 
sessions.
Outcome measures
Outcome measures included the total UPDRS III motor score 
(maximum 108) along with several motor subscores. Note 
that on this scale, a higher score indicates worse  performance. 
For individual subjects, a change of five points in the total 
UPDRS III motor score (4.6% of the maximum score) was 
considered to be a minimal clinically important change, 
as defined by Schrag et al (for patients in Hoehn and Yahr 
stages 1–3).17
All of the subscores except for tapping were based 
on  definitions used in previous studies: tremor = items 
20–21 assessed only at the hands (maximum 16);18,19 
 bradykinesia = items 23–26, 31 (maximum 36);20 gait = item 29 
(maximum 4);21 and posture = items 28, 30 (maximum 8).22 
The tapping subscore was defined as item 23 (maximum 8). 
The differences in mean scores obtained at the CDS and 
reduced amplitudes were calculated for each outcome mea-
sure and normalized by the maximum possible score for that 
particular measure to facilitate comparison across different 
measures. For each of the subscores, we have identified 
which measures exhibited a change . 25% of the maximum 
possible score.
Dose-response characteristics
To characterize the nature of the response to stimula-
tion, dose-response curves were produced for the overall 
UPDRS III and for each of the subscores. In these plots, 
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dosage is reported as stimulation condition, which was nor-
malized by the CDS amplitude for each subject. The response 
is reported as the change in the UPDRS score (or subscore) 
recorded at each altered stimulation amplitude with respect 
to the score (or subscore) recorded at the CDS condition of 
stimulation on that day.
The linearity of the dose-response curves for each 
subject was assessed by calculating the slopes of each of 
the  segments. If the response to stimulation was graded 
and linear, each decrement in stimulation would account 
for 30%–40% of observed maximum change in outcome 
measure (30% for MOD, 40% for LOW, and 30% for OFF). 
If the response exhibited a purely threshold (on/off) effect, 
one of the decrements in stimulation would account for 
100% of the change in outcomes. In this analysis, a subject 
was characterized as having a “threshold” dose-response 
characteristic if one decrement in stimulation accounted 
for $70% of the maximum performance change observed, 
which is the amount of change expected from two decre-
ments. Otherwise, the subject was characterized as having a 
“graded” dose-response characteristic.
Statistical analysis
Statistics were performed using IBM SPSS Statistics 
software version 20 (SPSS Inc, Chicago, IL). For each 
outcome measure, the two-tailed Wilcoxon signed rank 
test was used to compare the values measured at each 
session’s CDS amplitude with the values measured at that 
same session’s reduced amplitude. Performance at each 
session’s CDS amplitude was treated as a baseline measure 
for performance at the associated reduced amplitude to 
account for minor changes in medication or CDS settings 
over the course of all three test sessions. Unless otherwise 
noted, summary data is reported as the mean ± one stan-
dard deviation, and a P value , 0.05 was considered to be 
statistically significant.
Results
Dose-response characteristics
Although the mean dose-response curves for the subscores 
(Figure 1) were nearly linear, there was high variability across 
subjects. Applying the linearity criterion described above to 
the total UPDRS III motor score, four subjects exhibited a 
graded dose-response characteristic (3, 4, 6, and 7) and two 
exhibited a threshold response (1 and 2). The two subjects 
(5 and 8) who showed a very small overall change in the 
UPDRS III score were not included in this characterization 
of the dose-response curve.
Comparison across stimulation 
conditions
When amplitude was reduced from the CDS to the MOD con-
dition, only four subjects experienced a clinically important 
decrease in performance, and two of these decreases were 
only borderline, defined as 5–7 points (Figure 2, Table 2). 
However, all eight subjects experienced a clinically important 
change ($5 points) when amplitude was reduced from the 
CDS to the LOW condition (three designated as borderline 
changes). When amplitude was reduced to the OFF condition, 
six subjects showed clear deterioration in performance with 
increases in the total UPDRS III motor score ranging from 
13–59 points. Interestingly, two of the subjects (5 and 8) who 
only experienced borderline changes in the LOW condition 
did not experience a clinically important change in the OFF 
condition.
For the subscores, none of the subjects experienced 
change . 25% of the maximum score at the MOD condi-
tion, but half of the subjects experienced a change . 25% 
of the maximum score for at least one subscore at the LOW 
or OFF conditions. The other four subjects (3, 4, 5, and 8) 
did not experience a change . 25% of the maximum score 
in any condition.
When the subjects were examined as a group, none of 
the mean outcomes degraded significantly when ampli-
tude was decreased from the CDS to the MOD condition 
(Figure 3). However, all mean outcomes except one sig-
nificantly degraded when amplitude was decreased from 
the CDS to the LOW and OFF conditions (gait and posture, 
respectively).
Repeatability at CDS condition
Each subject had three scores obtained at the CDS condi-
tion, one from each data collection session (Table 2). For 
the total UPDRS III motor score, the difference in CDS 
measurements was calculated to determine if there were any 
clinically important changes between days. Subjects 3, 5, 6, 
and 7 experienced a clinically important change between 
at least two sessions. For the subscores, the range of these 
three measurements was calculated to characterize the vari-
ability in each subject’s results (Figure 1). Compared with 
the maximum possible score for each subscore, subjects 1, 
2, and 8 experienced low variability for all of the subscores. 
Subjects 3, 4, 6, and 7 experienced low variability on all but 
one subscore, and subject 5 experienced high variability for 
two subscores.
The range of CDS values was also compared with the 
change in score from the CDS condition to each reduced 
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A UPDRS part III
CDS range Change from CDS to reduced amplitudes 
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Figure 1 Day-to-day CDS variability compared to change in outcome measure from CDS to each reduced amplitude.
Notes: Left side of each lettered subplot represents each subject’s range of CDS values over the three sessions for (A) UPDRS Part III score, (B) tremor subscore, 
(C) bradykinesia subscore, (D) gait subscore, (E) posture subscore, and (F) tapping subscore. 
The horizontal line represents the mean, while the vertical bars represent each individual subject. Right side of each lettered subplot represents change in outcome measure from 
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Abbreviations: CDS, clinically determined stimulation; UPDRS, Unified Parkinson’s Disease Rating Scale; MOD, LOW and OFF, approximately 70%, 30% and 0% of CDS 
respectively.
amplitude condition. The mean change in score from the 
CDS to the MOD condition was comparable with the mean 
CDS range for the total UPDRS III score as well as for the 
tremor, bradykinesia, and tapping subscores, but the mean 
changes in score from the CDS to the LOW and OFF condi-
tions were greater than the mean CDS range. However, for 
the gait and posture subscores, the mean change in score 
from the CDS to the MOD condition was half the size of 
the mean CDS range, and the mean change in score from 
the CDS to the LOW condition was equal to the mean CDS 
range. For these two subscores, only the mean change in 
score from the CDS to the OFF condition was greater than 
the mean CDS range.
When examined for each subject, the change in score 
from the CDS to the MOD condition was greater than the 
CDS range for subjects 2 and 7 for the total UPDRS III 
score as well as the majority of the subscores. For the rest 
of the subjects, the change in score from the CDS to the 
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MOD condition was comparable with or less than the CDS 
ranges for the total UPDRS III score and the majority of 
the subscores. In contrast, the change in score from the 
CDS to the LOW condition exceeded the CDS range for 
the total UPDRS III score for all subjects except subject 
5 and for at least half of the subscores for subjects 1, 2, 
4, 6, and 7.
Discussion
Individual subject measures
Subjects 1 and 2 were both characterized as having a 
threshold in the dose-response curve. In addition, neither 
exhibited clinically significant day-to-day variability in the 
CDS measures. However, subject 2  experienced a greater 
change in score when amplitude was reduced to the MOD 
condition compared with the range of scores experienced 
during different CDS sessions, while subject 1 did not. This 
difference may be explained by the location of the thresholds 
for the two subjects. The threshold for subject 1 was located 
between the MOD and LOW conditions, with little difference 
observed between CDS and MOD.  However, the threshold for 
subject 2 was located between CDS and MOD and a reduction 
in stimulation amplitude of 30% accounted for more than 
80% of the total observed change in score.
Subjects 3, 6, and 7 were all characterized as having a 
graded dose response curve and all exhibited some clinically 
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significant variability in the CDS outcomes. For these sub-
jects, the graded response characteristic may be responsible 
for observed day-to-day variability as well as the sensitiv-
ity to changes in stimulation. The characteristics of these 
subjects demonstrate that at least some patients may benefit 
from fine-tuning of the stimulation level and possibly may 
benefit from a system that allows for daily adjustments to 
stimulation level either in an automated or patient-selected 
manner. However, subject 4 was also characterized as having 
a linear dose-response curve but did not exhibit clinically 
significant variability in CDS outcomes. This observation 
may be due to the fact that the total effect of stimulation 
was low in this subject and this was the only subject in the 
study who was not taking antiparkinsonian medications. 
Subjects 5 and 8 demonstrated less sensitivity to the degree 
of stimulation reduction compared with the other subjects, 
with the largest observed changes in the total UPDRS III 
score at less than 10.
DBS dose-response characteristics
Several studies have demonstrated the value of DBS by 
assessing motor function with and without stimulation, but 
very few have investigated more subtle changes in stimulation 
values. By assessing motor function at four different ampli-
tudes, we have been able to characterize the dose-response 
curves for individual subjects. With only four data points, this 
is a very coarse characterization of the dose-response curve, 
but does enable classification of different response charac-
teristics that may have implications for clinical adjustments 
to stimulation settings.
A linear dose-response curve would suggest that the 
effect of DBS could be precisely regulated by adjusting 
stimulation amplitude. Although the group means for the total 
UPDRS III score and each of the subscores all exhibited linear 
dose-response curves, the data demonstrated a high degree 
of variability across the set of subjects. These data reflect the 
variability observed clinically in the effects of Parkinson’s dis-
ease on motor performance and the variability in the reported 
on/off effects of DBS. Although a wide range of response 
characteristics was demonstrated across symptoms, six of the 
eight subjects could be grouped into one of two categories, 
comprising those who exhibited a threshold, ie, an all-or-none 
type of response to stimulation and those who exhibited a 
graded response that was approximately linear.
The two classes of dose-response characteristics that 
were observed may be due to differences in the nature and/
or stage of Parkinson’s disease or may be due to differences 
in electrode location. If this classification scheme were to be 
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Figure 3 Changes in mean (± standard error of the mean) UPDRS score/subscores from the CDS condition for each amplitude level. *Indicates changes in mean across 
subjects of each outcome that were significant. (A) UPDRS Part III score, (B) tremor subscore, (C) bradykinesia subscore, (D) gait subscore, (E) posture subscore, and 
(F) tapping subscore. 
Note: CDSM, CDSL, and CDSO: CDS amplitudes for the sessions in which amplitude was reduced to the MOD, LOW, and OFF levels, respectively.
Abbreviations: CDS, clinically determined stimulation; UPDRS, Unified Parkinson’s Disease Rating Scale; MOD, LOW and OFF, approximately 70%, 30% and 0% of CDS 
respectively.
confirmed in a larger study, the results could lead to the devel-
opment of alternative parameter selection procedures for use 
in the clinic: those exhibiting graded responses could have 
stimulation levels iteratively adjusted to improve  performance 
while those who exhibit threshold-like responses could 
have stimulation adjusted to just above their threshold in 
order to reduce battery power consumption. Perhaps more 
importantly, a larger study could also characterize electrode 
location to determine the degree to which dose-response 
classification is determined by surgical placement.
Comparison across stimulation 
conditions
Reducing the stimulation to the MOD condition caused a 
clinically important decrease in performance for half of 
the subjects, but further reductions (to the LOW and/or 
OFF setting) caused clinically important changes for all 
subjects. The lack of observed change at the MOD condition 
may truly reflect a lack of clinical effect or it may indicate 
a failure to detect the effect due to insufficient sensitivity 
in measurement procedures. Although the UPDRS III has 
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been found to be reliable and valid, it has been criticized 
for placing too much emphasis on severe manifestations of 
symptoms and not enough on milder presentations, such as 
might be seen if stimulation amplitude was reduced by only 
30%.23 In addition, the scale measures symptoms that are 
not experienced by every patient, which decreases its overall 
sensitivity.24 However, if there was indeed no significant 
change in performance at the MOD condition for some of 
the subjects, then stimulation amplitude could be reduced 
by at least 30% for these subjects and performance would 
not degrade.
Although many subjects experienced similar increases 
in their total UPDRS III motor scores and several even had 
similar raw scores at each amplitude condition, their per-
formance as measured by the subscores was very different. 
This may be explained by the differences in the subjects’ 
primary symptoms. Previous reports25 observed that although 
two patients may have the same UPDRS score, their qual-
ity of life may actually be very different depending on 
their prominent symptom(s), which suggests that adjusting 
stimulation parameters based on the total UPDRS III motor 
score alone may not always provide the most benefit for a 
patient’s functionality.
In current clinical practice, stimulation amplitude is 
often chosen primarily based on the presentation of tremor, 
because tremor responds almost instantaneously to changes 
in stimulation. Unfortunately, tremor has been shown not to 
be correlated with other components of motor performance, 
to have little relation to functional disability, and to have little 
impact on patient quality of life.25–27 It is possible that stimula-
tion amplitude should be set based on the response of other 
components of motor performance. Bradykinesia,  postural 
stability, gait, and rigidity ratings have been  suggested to 
be the most dominant factors contributing to disability in 
patients with Parkinson’s disease.27
Day-to-day variability
Across the three sessions, four of the subjects (1, 2, 4, 8) 
exhibited consistent UPDRS III motor scores at the CDS 
amplitude, and four subjects (3, 5, 6, 7) exhibited a range of 
CDS scores that exceeded the criterion for minimal clinically 
important change. For comparison, the change in stimulation 
to the MOD condition produced a similar result: four subjects 
exhibited no clinically important change and four exhibited 
clinically important changes. The fact that half of the sub-
jects exhibited clinically significant differences across days 
with the same stimulation settings indicates that day-to-day 
variability in motor performance is substantial and strongly 
cautions against the use of a single UPDRS reading in setting 
DBS parameters.
This study did not restrict changes in clinical prescrip-
tion of stimulation or medication over the course of the 
subject’s participation in the study, but it is important to 
note that these changes did not coincide with any of the 
observed clinically significant day-to-day variability in 
CDS scores. For subjects 3 and 6, although there were no 
changes in the CDS levels between sessions 1 and 2, there 
were clinically significant changes in the total UPDRS III 
scores observed at the CDS settings (from 12 to 7 for subject 
3; from 5 to 13 for subject 6). Between sessions 2 and 3, 
the CDS levels had been changed for both subjects (values 
reported in Table 1), but there was only a small change in 
UPDRS score (from 7 to 11 for subject 3; from 13 to 15 for 
subject 6). For subjects 1, 2 and 8, there were changes in the 
levodopa equivalent daily dose and/or stimulation settings 
across the set of sessions, but none of these changes coin-
cided with clinically significant variability in the UPDRS 
scores measured at CDS.
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